A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
M.D. Anderson Cancer Center
Summary
To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.
Description
Primary Objectives: To determine the safety of mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalidomide in relapsed/refractory NHL. To determine the best overall response rate (ORR) of the combination of mosunetuzumab, with polatuzumab vedotin, tafasitamab, and lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma. Secondary Objectives: To determine the complete response rate, duration of response, progression free survival, and overall survival in patients with DLBCL following treatment with of mosunetuzumab, polatuzumab vedotin, tafasitamab, and lenalid…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion criteria: Patients in safety run in must meet the following criteria for study entry: * A diagnosis of relapsed CD20+ Follicular Lymphoma grade 1-3a * A diagnosis of relapsed CD20+ diffuse large B-cell lymphoma Patients in dose expansion must meet the following criteria for study entry: • A diagnosis of relapsed CD20+ diffuse large B-cell lymphoma Patients in each component (safety run in and dose expansion) must meet the following criteria for study entry: 1. Evidence of progression or lack of response following at least 1 prior treatment 2. Able and willing to provide written…
Interventions
- DrugMosunetuzumab
Given by IV (vein)
- DrugPolatuzumab vedotin
Given by IV (vein)
- DrugTafasitamab
Given by IV (vein)
- DrugLenalidomide
Given by PO
Location
- M D Anderson Cancer CenterHouston, Texas